{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 39,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide is split into a 2022 review on the left and a corporate vision statement on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/4",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.18,
        "y": 0.28
      },
      "kind": "list",
      "text": "Preliminary Phase 1 data presented at EORTC-NCI-AACR: ARROS-1 Phase 1/2 study of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37bb8138-1fee-4ed6-8036-9f2f470e8961",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.69
      },
      "kind": "list",
      "text": "Continued advancement of internal research & discovery pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6da2c974-6f01-48db-9242-8db434fde8d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.77
      },
      "kind": "list",
      "text": "Continued team growth (60+ FTEs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7206c77c-6c2a-4acf-90ee-adb0aac2cca7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.61
      },
      "kind": "list",
      "text": "Nominated 3rd development candidate: NVL-330, a HER2ex20-selective inhibitor",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9828a4c8-3c2f-48e9-a369-d1b28f0b9e97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.18,
        "y": 0.42
      },
      "kind": "list",
      "text": "Trial initiated for parallel lead program: ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors, with update on preliminary dose-escalation data expected in 2H’23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6302f93-a2ee-421a-92aa-9615757040f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.84
      },
      "kind": "list",
      "text": "$264.5M upsized financing expected to extend cash runway into 2nd half of 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcb56ed9-ec22-4998-8ebb-69213645de6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.335,
        "x": 0.615,
        "y": 0.498
      },
      "kind": "paragraph",
      "text": "Fully integrated pharmaceutical company with the goal of translating deep expertise in chemistry & structure-based drug design into best-in-class small molecule medicines for patients with cancer",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3364a62c-8fd0-4fe2-8659-06197fbf5fe3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "2022 IN REVIEW",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21abb22f-17d2-42f7-86f3-cb9e78efd26b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.1,
        "x": 0.733,
        "y": 0.318
      },
      "kind": "title",
      "text": "Vision",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36b71de9-14a0-4cbd-b4d2-d84bbab3a1ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.27,
        "x": 0.648,
        "y": 0.395
      },
      "kind": "title",
      "text": "Discover, Develop & Deliver",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0556aef4-98da-45f4-9059-c40cd717b3eb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "35359b55-6745-441b-9afa-2c0f8281d507",
      "evidence": "paragraph/paragraph: Fully integrated pharmaceutical company with the goal of translating deep expertise in chemistry & structure-based drug design into best-in-class small molecule medicines for patients with cancer",
      "confidence": 0.8
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f5050a4d-c37a-4579-afec-0abc9ab351a7",
      "evidence": "list/bullet: Trial initiated for parallel lead program: ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors, with update on preliminary dose-escalation data expected i",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}